Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

MA Matthay, CS Calfee, H Zhuo… - The Lancet …, 2019 - thelancet.com
Background Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has
shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety …
被引用次数：555 相关文章

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

MA Matthay, CS Calfee, H Zhuo… - The Lancet …, 2019 - experts.umn.edu
BACKGROUND: Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs)
has shown benefits in preclinical models of acute respiratory distress syndrome (ARDS) …

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.

MA Matthay, CS Calfee, H Zhuo… - The Lancet …, 2019 - escholarship.org
BackgroundTreatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has
shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety …
[HTML] nih.gov

[HTML][HTML] Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a …

MA Matthay, CS Calfee, H Zhuo… - The Lancet …, 2019 - ncbi.nlm.nih.gov
Background Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has
shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety …
[PDF] remescor.com

[PDF][PDF] Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety …

MA Matthay, CS Calfee, H Zhuo, BT Thompson… - 2018 - remescor.com
Background Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has
shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety …

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

MA Matthay, CS Calfee, H Zhuo… - The Lancet …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has
shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety …

[引用][C] Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety …

MA Matthay, CS Calfee, H Zhuo, BT Thompson… - The Lancet Respiratory …, 2019 - cir.nii.ac.jp
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory
distress syndrome (START study): a randomised phase 2a safety trial | CiNii Research CiNii …
[PDF] archive.org

[PDF][PDF] Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety …

MA Matthay, CS Calfee, H Zhuo, BT Thompson… - Lancet, 2019 - scholar.archive.org
Background—Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has
shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety …
[PDF] primecell.eu

[PDF][PDF] Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety …

MA Matthay, CS Calfee, H Zhuo, BT Thompson… - 2018 - primecell.eu
Background Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has
shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety …

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.

MA Matthay, CS Calfee, H Zhuo… - The Lancet …, 2018 - europepmc.org
Background Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has
shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety …